Evaluating COPD in the Brazilian population
Official title: Prospective Multicentric Cohort Study of Severe and Very Severe COPD Patients in Brazil.
Run by AstraZeneca · NCT06780046 · Data updated 2026-11-12
This study is trying to learn more about how severe COPD affects people in different parts of Brazil by following patients for a year to see how their condition changes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 693 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Locations | 10 sites (Aparecida de Goiânia and 9 other locations) |
| Status | Recruiting |
| Started | January 31, 2025 |
| Main results expected | September 30, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT06780046 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with confirmed severe or very severe COPD.
✕Probably not a fit
Patients with advanced fibrosing interstitial lung disease, high-risk pulmonary hypertension, or active cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, prospective, multicenter cohort study aims to include patients with severe and very severe Chronic Obstructive Pulmonary Disease (COPD) according to the GOLD 2024 guidelines. The study will enroll patients from various regions of Brazil, each with different risk factors and population characteristics, to gather comprehensive data on COPD exacerbation rates and disease progression. Participants will be followed for 12 months with on-site visits and tele-consults to monitor their condition and collect relevant clinical data.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the management and treatment of severe COPD in the Brazilian population.
How similar studies have gone: While this study focuses on a specific population in Brazil, similar observational studies have shown success in understanding COPD in diverse populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT \>=10); or * GOLD E (\>=2 moderate or 1 severe exacerbation - hospitalization); or * GOLD 3 and 4 (FEV1 \<50%). Exclusion Criteria: * Advanced fibrosing interstitial lung disease (extent \>=50%); and/or * High-risk pulmonary hypertension (on triple therapy); and/or * Active cancer - on systemic therapy
Where it's running
-
Research Site
Aparecida de Goiânia, Brazil Recruiting -
Research Site
Bahia, Brazil Recruiting -
Research Site
Belém, Brazil Recruiting -
Research Site
Brasília, Brazil Recruiting -
Research Site
Campo Grande, Brazil Recruiting -
Research Site
Florianópolis, Brazil Recruiting
Show 4 more locations
-
Research Site
Goiânia, Brazil Recruiting -
Research Site
Santo André, Brazil Recruiting -
Research Site
São Paulo, Brazil Recruiting -
Research Site
Uberlândia, Brazil Recruiting
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Enhanced COPD care for people being checked for lung cancer
This project will test whether finding and treating COPD early in people being checked for possible lung cancer helps symptoms, lung function, and overall care.
-
High-Flow Nasal Cannula vs Noninvasive Ventilation in COPD with Hypercapnia
This study tests whether a high-flow nasal cannula can better support gas exchange and comfort compared with noninvasive ventilation in COPD patients with mild-to-moderate elevated CO2.
-
Risk-based lung cancer screening in COPD patients using ML and clinical models
This study tests whether a PLCOm2012 risk model plus a machine learning model can spot COPD patients at high risk for lung cancer to see if they benefit from low-dose CT screening.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
-
Nebulized vs handheld maintenance therapy for COPD patients with limited benefit from inhalers
This trial tests whether switching to a breath-enhanced nebulizer with similar COPD meds helps people who don’t get enough relief from their current handheld inhalers.
-
New breathing tests to diagnose airway disease in hospital and community settings
This study tests whether newer breathing tests can correctly diagnose COPD and airway disease as well as standard spirometry, using tests like capnography and oscillometry in hospital and community settings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.